A Platform Study of Epigenetic Therapy Before Prostatectomy in Men With Prostate Cancer

This is an open-label, non-randomized, exploratory platform protocol designed to assess the safety and antitumor activity of epigenetic therapies in participants with localized prostate cancer who are undergoing radical prostatectomy. The epigenetic therapy is intended to increase the sensitivity of the underlying tumor to the patient's immune system. The platform study will evaluate safety, biomarkers, and clinical activity of an epigenetic therapy. The particular details relevant to each module within this platform study will be provided as appendices to the core protocol.

Trial Details

NCT ID
NCT06888102
Phase
EARLY_PHASE1
Sponsor
Edwin Posadas, MD
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Neoadjuvant Epigenetic Therapy
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368

Key Eligibility Criteria

  • Men electing to undergo radical prostatectomy with preoperative tissue available.
  • Age ≥18 years
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1
  • Adequate organ function defined by:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →